metformin hydrochloride sustained-release

Metformin hydrochloride sustained-release is an oral antihyperglycemic small molecule drug developed by Hubei Huaxin Pharmaceutical for the management of Type 2 diabetes. As a biguanide, metformin works primarily by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Its molecular mechanism is widely associated with the activation of AMP-activated protein kinase (AMPK), an enzyme that plays a crucial role in cellular energy homeostasis. This specific sustained-release formulation is engineered to provide a controlled release of the active ingredient over an extended period, which typically allows for once-daily dosing and may improve gastrointestinal tolerability compared to immediate-release versions.

Other names

Metformin HCl extended-release tabletsMetformin XR盐酸二甲双胍缓释片